Immunological aspects of patients with HIV-1 disease following immunization with recombinant gp160 (VaxSyn).

Antibiotics and chemotherapy

Volumn 48, Issue , 1996, Pages 147-154

  Guerra, E ^a   Ricci, G ^a   Carlesimo, M ^a   Varani, A R ^a   Pontesilli, O ^a   Scala, E ^a   Mezzaroma, I ^a   Pierdominici, ^a   Pandolfi, F ^a   Antinori, A ^a   De Luca, A ^a   Murri, R ^a   Ammassari, A ^a   Ortona, L ^a   Aiuti, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT VACCINE; VAXSYN HIV 1 (GP160) VACCINE; VAXSYN HIV-1 (GP160) VACCINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTIVE IMMUNIZATION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS VACCINES; ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HIV-1; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; VACCINES, SYNTHETIC; ZIDOVUDINE;

EID: 0029691613     PISSN: 00664758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)